The incidence of many cancer types is significantly reduced in individuals with Down's syndrome 1-4 , and it is thought that this broad cancer protection is conferred by the increased expression of one or more of the 231 supernumerary genes on the extra copy of chromosome 21. One such gene is Down's syndrome candidate region-1 (DSCR1, also known as RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)mediated angiogenic signalling by the calcineurin pathway [5] [6] [7] [8] [9] [10] .
Here we show that DSCR1 is increased in Down's syndrome tissues and in a mouse model of Down's syndrome. Furthermore, we show that the modest increase in expression afforded by a single extra transgenic copy of Dscr1 is sufficient to confer significant suppression of tumour growth in mice, and that such resistance is a consequence of a deficit in tumour angiogenesis arising from suppression of the calcineurin pathway. We also provide evidence that attenuation of calcineurin activity by DSCR1, together with another chromosome 21 gene Dyrk1a, may be sufficient to markedly diminish angiogenesis. These data provide a mechanism for the reduced cancer incidence in Down's syndrome and identify the calcineurin signalling pathway, and its regulators DSCR1 and DYRK1A, as potential therapeutic targets in cancers arising in all individuals.
Down's syndrome is the most common genetic cause of mental retardation in humans, occurring in 1 out of 700 live births. Epidemiological studies suggest that although individuals with Down's syndrome have an increased risk of leukaemia, they have a considerably reduced incidence of most solid tumours 1-4 . In the largest study to date involving 17,800 Down's syndrome individuals, the mortality from cancers was ,10% of expected 4 . Such data indicate that one or more of the 231 trisomic genes on chromosome 21 is responsible for protecting these individuals against cancer. Of note, Down's syndrome individuals also have a reduced incidence of other angiogenesis-related diseases, such as diabetic retinopathy 11 and atherosclerosis 12 , suggesting that cancer protection in the Down's syndrome population may be due, in part, to angiogenesis suppression.
The DSCR1 gene lies on chromosome 21 and encodes a negative regulator of VEGF-calcineurin signalling in the endothelium [5] [6] [7] [8] [9] [10] . Previous studies have demonstrated that gross overexpression of DSCR1 in endothelial cells blocks VEGF-mediated angiogenic responses in vitro [7] [8] [9] [10] . We examined DSCR1 protein expression in Down's syndrome human fetal tissues and observed a consistent 1.8-fold increase in DSCR1 levels in tissues from Down's syndrome embryos, as well as increased expression of DSCR1 fetal isoforms 5 , compared with those from age-matched control fetuses ( Fig. 1a ). Substantial synteny exists in gene identity and order between much of human chromosome 21 and the mouse 13 . The Ts65Dn mouse model of Down's syndrome is trisomic for 104 of the 231 genes on human chromosome 21, including DSCR1 (ref. 14) ( Supplementary  Fig. 1a ). We probed tissues from Ts65Dn mice to ascertain whether DSCR1 was also upregulated in the Ts65Dn mouse and found a 1.7fold increase in DSCR1 protein expression compared with diploid littermates ( Supplementary Fig. 1b ). Thus, DSCR1 expression in Ts65Dn mice is increased in an analogous fashion to DSCR1 expression in Down's syndrome fetal tissues.
We proposed that the inhibition of tumorigenesis in the Down's syndrome population may be partially due to the suppression of tumour angiogenesis, thus predicting that the inhibitory effect of DSCR1 trisomy on tumour growth occurs within the host tumour microenvironment. To establish whether the Ts65Dn Down's syndrome mouse, like Down's syndrome individuals, exhibits generalized protection from cancers, we assayed the growth of two transplantable tumour models: Lewis lung carcinoma and B16F10 melanoma cells. We observed considerable growth suppression of both Lewis lung and B16F10 tumour cells in Ts65Dn mice relative to littermate controls ( Fig. 1b ), correlating with a significant decrease in microvessel density ( Fig. 1c ). Endothelial cells isolated from Ts65Dn mice demonstrated upregulation of Dscr1 mRNA in contrast to diploid littermates ( Supplementary Fig. 1c ) and were notably less responsive to VEGFmediated proliferation in vitro ( Supplementary Fig. 1d ), further implicating an angiogenic defect in these mice. Thus, trisomy for orthologues of half the genes on human chromosome 21 was sufficient to slow ectopic tumour growth.
To validate that the compromised angiogenesis we observed in murine models of Down's syndrome extended to human cells carrying trisomy 21, we compared microvessel density in teratomas derived from Down's syndrome induced pluripotent stem (iPS) cells versus those from cytogenetically normal iPS cells from a healthy volunteer 15 . These iPS cell lines were inoculated intramuscularly into immunodeficient mice (Rag2 2/2 Il2rg 2/2 ), and angiogenesis was assessed in the resulting tumours using a human-specific antibody to the endothelial marker CD31 (ref. 16 ). Microvessel density was significantly reduced in teratomas derived from Down's syndrome iPS cells compared to iPS cells from the normal control ( Fig. 1d and Supplementary Fig. 1e ).
Given that Ts65Dn mice are trisomic for 104 genes, we next determined whether three copies of Dscr1 alone would be sufficient to suppress tumorigenesis. We generated a Dscr1 transgenic mouse targeting a Myc-tagged Dscr1 complementary DNA driven by its native promoter to the Hprt1 locus ( Supplementary Fig. 2a, b ). Expression of the targeted third copy of Dscr1 was verified by western blot analysis on isolated endothelial cells ( Supplementary Fig. 2c ), and quantitative PCR analysis demonstrated a 2.4-fold increase in Dscr1 messenger RNA relative to littermate controls (Supplementary Fig. 2d ). To ensure that one extra copy of Dscr1 was sufficient to restrain VEGF-calcineurin signalling, we examined NF-ATc1 subcellular localization as a measure of calcineurin activation ( Fig. 2a ).
After VEGF treatment, endothelial cells isolated from Dscr1 transgenic mice exhibited predominantly cytoplasmic NF-ATc1 localization, whereas wild-type endothelial cells showed the expected nuclear localization ( Fig. 2a ). Dscr1 transgenic endothelial cells also exhibited decreased sensitivity to VEGF relative to wild-type endothelial cells, as assessed by VEGF-induced proliferation (Fig. 2b) .
Substantial growth inhibition of Lewis lung carcinoma and B16F10 melanoma cells was observed in Dscr1 transgenic mice ( Fig. 2c) , with a corresponding decrease in microvessel density (Fig. 2d ), as compared with tumours from wild-type littermates. Quantification of endothelial cells in tumours isolated from Dscr1 transgenic and wild-type mice by flow cytometry showed a significant decrease in CD31 1 CD45 2 cells in tumours from Dscr1 transgenic mice (Supplementary Fig. 3a ). Furthermore, many of the CD31-reactive microvessels in tumours isolated from Dscr1 transgenic mice lacked functional lumens as evidenced by the absence of co-staining with circulating fluorescein isothiocyanate (FITC)-lectin and CD31positivity ( Supplementary Fig. 3b ). Immunostaining with CD31 and Myc antibodies confirmed specific expression of the DSCR1 transgene in the tumour endothelium of Dscr1 transgenic animals ( Fig. 2e) . Thus, a single extra copy of Dscr1 seems to be sufficient to blunt host angiogenic responses and suppress tumour angiogenesis and tumour growth. A subset of tumours initiate growth by co-opting existing host vessels 17 but the progressive growth and elaboration of new vessels accompanying tumour expansion requires neo-angiogenesis. To ascertain whether excess DSCR1 suppresses initial vessel co-option or subsequent angiogenesis, Dscr1 transgenic and wild-type mice were inoculated with reduced numbers of Lewis lung carcinoma cells to generate slowly growing tumours. DSCR1 increase inhibited the extended growth phase of transplanted tumours and not just their initial expansion ( Supplementary Fig. 3c ), supporting the notion that excess DSCR1 suppresses tumour angiogenesis.
To confirm whether tumour protection in the Ts65Dn mouse was specifically due to Dscr1 trisomy, we crossed the Ts65Dn mice to Dscr1 1/2 mice 18 generating Ts65Dn/Dscr1 1/2 animals with two copies of Dscr1 but maintaining trisomy for the other 103 genes ( Fig. 3a ). After validating both segmental trisomy and Dscr1 status ( Supplementary Fig. 4a , b), we compared flank tumour growth in diploid mice to that in Ts65Dn mice with two or three copies of Dscr1. Reduction to two Dscr1 copies in the Ts65Dn/Dscr1 1/2 mice significantly abrogated the tumour protection observed in the Ts65Dn parental mice (Fig. 3b ). Loss of the protective effect against tumour growth was mirrored by a corresponding increase in microvessel density in tumours from Ts65Dn/Dscr1 1/2 mice relative to their Ts65Dn littermates ( Fig. 3c ), confirming the pivotal role of Dscr1 in tumour suppression in the Ts65Dn Down's syndrome mouse model. Together, our data provide strong support for the notion that one extra copy of Dscr1 is necessary for maximal suppression of tumour growth via inhibition of tumour angiogenesis.
Increased dosage of Dscr1 might suppress angiogenesis by downregulating expression of calcineurin-NFAT-dependent targets in endothelial cells. Cyclooxygenase 2 (COX-2, also known as PTGS2) has been identified as a calcineurin-dependent gene and an important mediator of the angiogenic response to VEGF 19 . Quantitative PCR and western blot analysis of COX-2 expression in Dscr1 transgenic endothelial cells demonstrated a substantial decrease in COX-2 levels relative to control littermates ( Fig. 4a, b ), suggesting that a modest increase in DSCR1 expression suppresses the expression of COX-2 and probably other VEGF-responsive targets. Although Dscr1 trisomy has an important role in preventing tumour angiogenesis in our Down's syndrome mouse model, there are clearly other chromosome 21 genes that contribute to the tumour suppressive effects observed in the Ts65Dn mouse. Because increased dosage of Dscr1 attenuates VEGF-calcineurin-NFAT signalling, we examined the role of Dyrk1a, another chromosome 21 gene known to regulate NFAT signalling and contribute to other Down's syndrome phenotypes 20, 21 . After confirmation of Dyrk1a expression in endothelial cells ( Supplementary Fig. 4c ), we examined the effects of Dyrk1a upregulation with Dscr1 trisomy after overexpression of Dyrk1a into Dscr1 transgenic endothelial cells (Fig. 4c ). VEGF-mediated endothelial proliferation was markedly inhibited as a consequence of increased expression of both DYRK1A and DSCR1 (Fig. 4d VEGF-calcineurin-NFAT signalling in endothelial cells. By disrupting the balance of NFAT phosphorylation, DYRK1A blocks transactivation of NFAT-dependent target genes 20, 21 . Other trisomy 21 genes may inhibit tumour development via cancer cell autonomous mechanisms. A recent study using the Ts65Dn mouse on the APC min mice background demonstrated that three copies of the Ets2 proto-oncogene reduced the incidence of spontaneous intestinal tumours 22 . However, examination of a spontaneous tumour model prevents the distinction of Ets2 dosage effects on tumour initiation versus progression. In contrast, our work specifically investigates suppression of tumour progression as a consequence of Dscr1 trisomy. Further studies are necessary to determine the magnitude and synergy of these genes in suppressing tumour growth in both the Ts65Dn mouse and the Down's syndrome population.
Our studies implicate DSCR1-dependent inhibition of the VEGFcalcineurin-NFAT pathway in endothelial cells as an important component of the reduced cancer incidence in Down's syndrome individuals. Hence, it is reasonable to speculate that cyclosporin A and FK506, immunosuppressive drugs that specifically inhibit calcineurin 23 , would also suppress tumour angiogenesis. Surprisingly, several clinical studies indicate that a significant increase in cancer incidence is a serious complication of transplant recipients receiving long-term immunosuppressive therapy 24 . The mechanism behind this increased rate of cancer is not yet understood, however, such studies point to an important distinction between the calcineurininhibitory action of DSCR1 and those of cyclosporin A and FK506.
The cancer protection observed in Down's syndrome individuals is remarkable given the heterogeneous mechanisms used among tumours. Although Down's syndrome individuals have less exposure to environmental and other factors that contribute to tumour incidence, the implication remains that one or more of the trisomic genes on chromosome 21 exert an anti-neoplastic effect, presumably by modulating some fundamental aspect of tumour initiation and/or progression. Microscopic avascular tumours represent the earliest stages of human neoplasias and are commonly observed in many organs after autopsy 25 . These data suggest that progression into macroscopic tumours, not tumour initiation, may be rate-limiting in human cancers. Such progression is critically dependent on interactions between the incipient tumour and its microenvironmentmost notably, activation of the 'angiogenic switch'. The pivotal role played by DSCR1 in tumour angiogenesis makes it a compelling candidate for cancer protection in the Down's syndrome population. Our data implicate VEGF-calcineurin-NFAT as a critical signalling axis in endothelial cells and suggests that maximal suppression of calcineurin requires increased expression of both Dscr1 and Dyrk1a. Further studies will be required to explore whether angiogenesis in general may also be impaired in the Ts65Dn mouse and in Down's syndrome individuals. Finally, our studies in the Ts65Dn mouse and transgenic tri-allelic Dscr1 mouse demonstrate the in vivo relevance of a modest excess of Dscr1 arising from trisomy, which is sufficient to negatively regulate tumour growth by dampening VEGFcalcineurin signalling. By analogy, we conclude that the increased expression of Dscr1 in individuals with trisomy 21 is probably a significant contributor to the decreased cancer incidence in this population. It is, perhaps, inspiring that the Down's syndrome population provides us with new insight into mechanisms that regulate cancer growth and, by so doing, identifies potential targets for tumour prevention and therapy.
METHODS SUMMARY
Western blot analysis. Fourteen-week-old human fetal kidney and liver tissue were isolated from control and Down's syndrome tissue, lysed in RIPA buffer and quantified for protein concentration. Tissue lysates were separated by SDS-PAGE, probed with anti-DSCR1 monoclonal antibody 18 and detected by chemiluminescence. Blots were stripped and re-probed with b-actin. DSCR1 levels were quantified by densitometric analysis in the linear range and compared to b-actin. Ts65Dn mice, diploid littermates and Dscr1-null mice were euthanized between 8 to 12 weeks of age, their brains were dissected and probed as described above. Human microvascular endothelial cells were lysed and probed with anti-DYRK1A monoclonal antibody. Tumour models. Six-ten-week-old mice were inoculated with 1-5 3 10 5 Lewis lung carcinoma or B16F10 melanoma cells in HBSS into the subcutaneous flank region as previously described 6 . Human iPS cell-derived teratomas were generated as previously described 15 . Immunohistochemistry. Mice were killed and tumours were collected and fixed in neutral-buffered formalin for paraffin embedding. Sections were deparaffinized and epitopes unmasked as previously described 6 . Sections were immunostained with rat anti-CD31 monoclonal antibody or anti-Myc polyclonal antibody overnight at room temperature, followed by incubation with goat anti-rat Alexa 594 and goat anti-rabbit Alexa 488, stained with Hoechst and analysed using AxioVision 4.0 software (Carl Zeiss Vision). Endothelial cell isolation, immunofluorescence and proliferation. Fourweek-old Dscr1 transgenic or littermate control mice were killed, lungs were removed, and endothelial cells were isolated as previously described 6 . For immunofluorescence, endothelial cells were plated on gelatine-coated coverslips, fixed with paraformaldehyde, blocked, permeabilized and incubated with anti-NF-ATc1 monoclonal antibody followed by goat anti-mouse Alexa 594. For proliferation assays, endothelial cells were plated in triplicate in tissue culture wells coated with 0.2% gelatin as previously described 6 , and treated with the indicated concentrations of VEGF. 
